Amneal moves to buy Kashiv in $1.1B biosimilars push
Bottom line
Amneal Pharmaceuticals said on April 22, 2026, that it has agreed to acquire Kashiv BioSciences in a deal valued at about $1.1 billion, including $375 million in cash, $375 million in Amneal equity at closing, and up to $350 million tied to regulatory and commercial milestones. Amneal said the acquisition would give it full control of Kashiv’s biosimilars development and manufacturing capabilities, building what it called a fully integrated global biosimilars platform. The companies already have a history together: Amneal completed its acquisition of Kashiv Specialty Pharmaceuticals in 2021, and Kashiv-developed biosimilars such as filgrastim and pegfilgrastim have already been part of Amneal’s portfolio. The new deal is expected to close in the second half of 2026. (investors.amneal.com)
Why it matters: For veterinary professionals, this is mainly a signal about where the broader biologics and biosimilars market is heading. While the transaction is centered on human medicines, it underscores continued investment in lower-cost biologic alternatives, manufacturing scale, and commercialization infrastructure. That matters because the same pricing, supply, and regulatory dynamics shaping human biosimilars often influence expectations for specialty pharmaceuticals more broadly, including how veterinary teams think about affordability, access, and future biologic competition for pet parents. Amneal is framing the move around a coming wave of biologic patent expirations, and analysts noted the deal could generate $400 million to $500 million in synergies. (investors.amneal.com)
What to watch: Watch for closing conditions in the second half of 2026, any antitrust or regulatory disclosures, and whether Amneal accelerates launches from Kashiv’s biosimilar pipeline, including its omalizumab candidate now under FDA review. (wsau.com)
Amneal Pharmaceuticals is making a major bet on biosimilars, announcing April 22, 2026, that it will acquire Kashiv BioSciences in a transaction worth about $1.1 billion. The structure includes $375 million in cash, $375 million in equity at closing, and up to $350 million in additional payments tied to regulatory milestones, royalties, and funding through close. Amneal said the acquisition would create a fully integrated global biosimilars platform and position the company for the next decade of biologic patent expirations. (investors.amneal.com)
The deal builds on an existing relationship rather than creating a new one. In April 2021, Amneal completed its acquisition of a 98% interest in Kashiv Specialty Pharmaceuticals, a Kashiv subsidiary focused on complex generics, drug delivery technologies, and 505(b)(2) products. Amneal and Kashiv have also worked together on biosimilars already on the market, including RELEUKO and FYLNETRA, suggesting this latest transaction is an expansion of a long-running strategic partnership into full ownership of the broader biosimilars business. (investors.amneal.com)
Amneal is pitching the acquisition as a scale move timed to a large market opportunity. In its announcement, the company pointed to a projected $300 billion-plus global biologics loss-of-exclusivity wave over the next decade. Reuters reported that Amneal expects $400 million to $500 million in synergies from the transaction, and said the company expects the deal to close in the second half of 2026. On the same day, Amneal also reported preliminary first-quarter 2026 revenue of $723 million and raised its standalone full-year guidance, including adjusted diluted EPS to $0.95 to $1.05 from $0.93 to $1.03, suggesting management wanted to present the acquisition as part of a broader growth story rather than a defensive move. (investors.amneal.com)
The pipeline is a key part of the rationale. Kashiv is one of a relatively small group of U.S.-based companies with end-to-end biosimilar development and manufacturing capabilities, according to Amneal. Their partnership has already produced marketed biosimilars, and in September 2025 Amneal announced a BLA submission for a proposed omalizumab biosimilar developed by Kashiv. Independent pipeline tracking from early 2026 indicated that candidate was under FDA review with an expected BsUFA action date in the third quarter of 2026. Amneal’s own materials have pointed to multiple biosimilar launches across 2026 and 2027, reinforcing that the acquisition is about near-term commercialization as much as long-term pipeline depth. (investors.amneal.com)
Public expert reaction was limited in the first 48 hours after the announcement, but the industry framing was consistent: this is a consolidation play aimed at capturing more value across the biosimilars chain. Trade coverage emphasized Kashiv’s manufacturing and pipeline capabilities, while Reuters highlighted the scale of the biologics patent cliff and the expected synergy opportunity. That interpretation appears well supported by the companies’ own messaging, which repeatedly emphasizes integration, affordability, and commercialization leverage. (americanpharmaceuticalreview.com)
Why it matters: For veterinary professionals, there’s no direct companion-animal product angle in this transaction today. Still, the deal is relevant as a readout on the biologics market more broadly. Biosimilars remain a closely watched model for improving access to high-cost therapies, and large transactions like this show manufacturers still see long-term value in building domestic development, manufacturing, and distribution capacity. For veterinary teams, especially those following specialty therapeutics, oncology, or immunology, that broader market direction matters because it can shape pricing expectations, supply resilience, and pet parent awareness of lower-cost biologic alternatives over time. That last point is an inference based on how human pharmaceutical market dynamics often influence expectations in adjacent healthcare sectors. (investors.amneal.com)
Amneal’s move also reflects a larger competitive reality: biosimilars are no longer just a portfolio add-on. They’re becoming a platform business that depends on manufacturing control, regulatory execution, and payer-ready commercialization. Companies that can manage all three may be better positioned as more complex biologics lose exclusivity, especially in immunology and oncology. (investors.amneal.com)
What to watch: The immediate next steps are closing approvals and any related filings as the companies target a second-half 2026 close. Beyond that, the most important near-term milestone may be the FDA review of the Kashiv-developed omalizumab biosimilar, along with any updates on additional launches Amneal has forecast for 2026 and 2027. If those programs move on schedule, this acquisition could quickly shift from a strategic announcement to an operating story with measurable commercial impact. (wsau.com)